New directions in pain management

Pain medicine is one of the most rapidly developing medical specialties of today. While there are many modalities that can be used in managing the patient in pain, drug treatment remains, for the most part, the cornerstone of treatment. Opioids retain their position as the foundation of most analges...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drugs of Today 2002-02, Vol.38 (2), p.135
1. Verfasser: MacPherson, Ross D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 2
container_start_page 135
container_title Drugs of Today
container_volume 38
creator MacPherson, Ross D
description Pain medicine is one of the most rapidly developing medical specialties of today. While there are many modalities that can be used in managing the patient in pain, drug treatment remains, for the most part, the cornerstone of treatment. Opioids retain their position as the foundation of most analgesic strategies, although they tend to be used nowadays in combination with adjuvant analgesics such as paracetamol and nonsteroidal antiinflammatory drugs. The range of available opioids has also been expanded with drugs such as hydromorphone and oxycodone, originally developed almost a century ago. This expanded choice has resulted in the concept of opioid rotation in chronic pain states, an approach that is aimed at maintaining pain control while minimizing adverse effects. Nonsteroidal antiinflammatory drugs continue to play an important role, especially as adjuvants, and the development of drugs such as celecoxib and refecoxib, highly specific for the inhibition of cyclooxygenase 2 pathway has been a further advance. The treatment of neuropathic pain continues to be a challenge to the clinician. While this has traditionally been treated with drugs from the anticonvulsant, antiarrhythmic and anti-depressant groups, results from these treatments have often been less than satisfactory. This has led to the development of completely new drug classes that modulate neuronal transmission in pain pathways, some of which are derived from exotic animal sources, such as the conotoxins from the marine snail family and epibatidine from a species of frog. The role of cannabinoids remains controversial.
doi_str_mv 10.1358/dot.2002.38.2.668325
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmed_primary_12532190</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>12532190</sourcerecordid><originalsourceid>FETCH-LOGICAL-c328t-bd9d0c78415edeceb72966443e8ba6969c47c1da667604f984161308061fa4633</originalsourceid><addsrcrecordid>eNpFj8tOwzAQRb0A0VL4A4TCByTYHmdiL1HFS6ropqwtx56gIPJQHIT4e1ylEps7m3vm6jB2I3ghoNT3YZgLybksQBeyQNQgyzO2FmhMDsbAil3G-JkKJSp1wVZCliCF4Wt290Y_WWgn8nM79DFr-2x0KTrXuw_qqJ-v2HnjviJdn-6GvT89HrYv-W7__Lp92OUepJ7zOpjAfaWVKCmQp7qSBtMakK4dGjReVV4Eh1ghV41JRRTANUfROIUAG6aWv34aYpyosePUdm76tYLbo6VNlvZoaUFbaRfLhN0u2PhddxT-oZMi_AHQ5k6a</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>New directions in pain management</title><source>MEDLINE</source><source>Portico</source><creator>MacPherson, Ross D</creator><creatorcontrib>MacPherson, Ross D</creatorcontrib><description>Pain medicine is one of the most rapidly developing medical specialties of today. While there are many modalities that can be used in managing the patient in pain, drug treatment remains, for the most part, the cornerstone of treatment. Opioids retain their position as the foundation of most analgesic strategies, although they tend to be used nowadays in combination with adjuvant analgesics such as paracetamol and nonsteroidal antiinflammatory drugs. The range of available opioids has also been expanded with drugs such as hydromorphone and oxycodone, originally developed almost a century ago. This expanded choice has resulted in the concept of opioid rotation in chronic pain states, an approach that is aimed at maintaining pain control while minimizing adverse effects. Nonsteroidal antiinflammatory drugs continue to play an important role, especially as adjuvants, and the development of drugs such as celecoxib and refecoxib, highly specific for the inhibition of cyclooxygenase 2 pathway has been a further advance. The treatment of neuropathic pain continues to be a challenge to the clinician. While this has traditionally been treated with drugs from the anticonvulsant, antiarrhythmic and anti-depressant groups, results from these treatments have often been less than satisfactory. This has led to the development of completely new drug classes that modulate neuronal transmission in pain pathways, some of which are derived from exotic animal sources, such as the conotoxins from the marine snail family and epibatidine from a species of frog. The role of cannabinoids remains controversial.</description><identifier>ISSN: 1699-3993</identifier><identifier>ISSN: 1699-4019</identifier><identifier>DOI: 10.1358/dot.2002.38.2.668325</identifier><identifier>PMID: 12532190</identifier><language>eng</language><publisher>Spain</publisher><subject>Analgesics, Opioid - therapeutic use ; Animals ; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use ; Calcium Channel Blockers - therapeutic use ; Cannabinoids - therapeutic use ; Cyclooxygenase 2 ; Cyclooxygenase 2 Inhibitors ; Cyclooxygenase Inhibitors - pharmacology ; Cyclooxygenase Inhibitors - therapeutic use ; Enzyme Inhibitors - pharmacology ; Humans ; Isoenzymes - metabolism ; Membrane Proteins ; Mollusk Venoms - therapeutic use ; Neprilysin - antagonists &amp; inhibitors ; Nicotinic Antagonists - therapeutic use ; omega-Conotoxins - therapeutic use ; Pain - drug therapy ; Peripheral Nervous System - drug effects ; Prostaglandin-Endoperoxide Synthases - metabolism ; Receptors, Nicotinic - drug effects</subject><ispartof>Drugs of Today, 2002-02, Vol.38 (2), p.135</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c328t-bd9d0c78415edeceb72966443e8ba6969c47c1da667604f984161308061fa4633</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12532190$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MacPherson, Ross D</creatorcontrib><title>New directions in pain management</title><title>Drugs of Today</title><addtitle>Drugs Today (Barc)</addtitle><description>Pain medicine is one of the most rapidly developing medical specialties of today. While there are many modalities that can be used in managing the patient in pain, drug treatment remains, for the most part, the cornerstone of treatment. Opioids retain their position as the foundation of most analgesic strategies, although they tend to be used nowadays in combination with adjuvant analgesics such as paracetamol and nonsteroidal antiinflammatory drugs. The range of available opioids has also been expanded with drugs such as hydromorphone and oxycodone, originally developed almost a century ago. This expanded choice has resulted in the concept of opioid rotation in chronic pain states, an approach that is aimed at maintaining pain control while minimizing adverse effects. Nonsteroidal antiinflammatory drugs continue to play an important role, especially as adjuvants, and the development of drugs such as celecoxib and refecoxib, highly specific for the inhibition of cyclooxygenase 2 pathway has been a further advance. The treatment of neuropathic pain continues to be a challenge to the clinician. While this has traditionally been treated with drugs from the anticonvulsant, antiarrhythmic and anti-depressant groups, results from these treatments have often been less than satisfactory. This has led to the development of completely new drug classes that modulate neuronal transmission in pain pathways, some of which are derived from exotic animal sources, such as the conotoxins from the marine snail family and epibatidine from a species of frog. The role of cannabinoids remains controversial.</description><subject>Analgesics, Opioid - therapeutic use</subject><subject>Animals</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</subject><subject>Calcium Channel Blockers - therapeutic use</subject><subject>Cannabinoids - therapeutic use</subject><subject>Cyclooxygenase 2</subject><subject>Cyclooxygenase 2 Inhibitors</subject><subject>Cyclooxygenase Inhibitors - pharmacology</subject><subject>Cyclooxygenase Inhibitors - therapeutic use</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Humans</subject><subject>Isoenzymes - metabolism</subject><subject>Membrane Proteins</subject><subject>Mollusk Venoms - therapeutic use</subject><subject>Neprilysin - antagonists &amp; inhibitors</subject><subject>Nicotinic Antagonists - therapeutic use</subject><subject>omega-Conotoxins - therapeutic use</subject><subject>Pain - drug therapy</subject><subject>Peripheral Nervous System - drug effects</subject><subject>Prostaglandin-Endoperoxide Synthases - metabolism</subject><subject>Receptors, Nicotinic - drug effects</subject><issn>1699-3993</issn><issn>1699-4019</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFj8tOwzAQRb0A0VL4A4TCByTYHmdiL1HFS6ropqwtx56gIPJQHIT4e1ylEps7m3vm6jB2I3ghoNT3YZgLybksQBeyQNQgyzO2FmhMDsbAil3G-JkKJSp1wVZCliCF4Wt290Y_WWgn8nM79DFr-2x0KTrXuw_qqJ-v2HnjviJdn-6GvT89HrYv-W7__Lp92OUepJ7zOpjAfaWVKCmQp7qSBtMakK4dGjReVV4Eh1ghV41JRRTANUfROIUAG6aWv34aYpyosePUdm76tYLbo6VNlvZoaUFbaRfLhN0u2PhddxT-oZMi_AHQ5k6a</recordid><startdate>20020201</startdate><enddate>20020201</enddate><creator>MacPherson, Ross D</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20020201</creationdate><title>New directions in pain management</title><author>MacPherson, Ross D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c328t-bd9d0c78415edeceb72966443e8ba6969c47c1da667604f984161308061fa4633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Analgesics, Opioid - therapeutic use</topic><topic>Animals</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</topic><topic>Calcium Channel Blockers - therapeutic use</topic><topic>Cannabinoids - therapeutic use</topic><topic>Cyclooxygenase 2</topic><topic>Cyclooxygenase 2 Inhibitors</topic><topic>Cyclooxygenase Inhibitors - pharmacology</topic><topic>Cyclooxygenase Inhibitors - therapeutic use</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Humans</topic><topic>Isoenzymes - metabolism</topic><topic>Membrane Proteins</topic><topic>Mollusk Venoms - therapeutic use</topic><topic>Neprilysin - antagonists &amp; inhibitors</topic><topic>Nicotinic Antagonists - therapeutic use</topic><topic>omega-Conotoxins - therapeutic use</topic><topic>Pain - drug therapy</topic><topic>Peripheral Nervous System - drug effects</topic><topic>Prostaglandin-Endoperoxide Synthases - metabolism</topic><topic>Receptors, Nicotinic - drug effects</topic><toplevel>online_resources</toplevel><creatorcontrib>MacPherson, Ross D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Drugs of Today</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MacPherson, Ross D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New directions in pain management</atitle><jtitle>Drugs of Today</jtitle><addtitle>Drugs Today (Barc)</addtitle><date>2002-02-01</date><risdate>2002</risdate><volume>38</volume><issue>2</issue><spage>135</spage><pages>135-</pages><issn>1699-3993</issn><issn>1699-4019</issn><abstract>Pain medicine is one of the most rapidly developing medical specialties of today. While there are many modalities that can be used in managing the patient in pain, drug treatment remains, for the most part, the cornerstone of treatment. Opioids retain their position as the foundation of most analgesic strategies, although they tend to be used nowadays in combination with adjuvant analgesics such as paracetamol and nonsteroidal antiinflammatory drugs. The range of available opioids has also been expanded with drugs such as hydromorphone and oxycodone, originally developed almost a century ago. This expanded choice has resulted in the concept of opioid rotation in chronic pain states, an approach that is aimed at maintaining pain control while minimizing adverse effects. Nonsteroidal antiinflammatory drugs continue to play an important role, especially as adjuvants, and the development of drugs such as celecoxib and refecoxib, highly specific for the inhibition of cyclooxygenase 2 pathway has been a further advance. The treatment of neuropathic pain continues to be a challenge to the clinician. While this has traditionally been treated with drugs from the anticonvulsant, antiarrhythmic and anti-depressant groups, results from these treatments have often been less than satisfactory. This has led to the development of completely new drug classes that modulate neuronal transmission in pain pathways, some of which are derived from exotic animal sources, such as the conotoxins from the marine snail family and epibatidine from a species of frog. The role of cannabinoids remains controversial.</abstract><cop>Spain</cop><pmid>12532190</pmid><doi>10.1358/dot.2002.38.2.668325</doi></addata></record>
fulltext fulltext
identifier ISSN: 1699-3993
ispartof Drugs of Today, 2002-02, Vol.38 (2), p.135
issn 1699-3993
1699-4019
language eng
recordid cdi_pubmed_primary_12532190
source MEDLINE; Portico
subjects Analgesics, Opioid - therapeutic use
Animals
Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
Calcium Channel Blockers - therapeutic use
Cannabinoids - therapeutic use
Cyclooxygenase 2
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors - pharmacology
Cyclooxygenase Inhibitors - therapeutic use
Enzyme Inhibitors - pharmacology
Humans
Isoenzymes - metabolism
Membrane Proteins
Mollusk Venoms - therapeutic use
Neprilysin - antagonists & inhibitors
Nicotinic Antagonists - therapeutic use
omega-Conotoxins - therapeutic use
Pain - drug therapy
Peripheral Nervous System - drug effects
Prostaglandin-Endoperoxide Synthases - metabolism
Receptors, Nicotinic - drug effects
title New directions in pain management
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T17%3A00%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20directions%20in%20pain%20management&rft.jtitle=Drugs%20of%20Today&rft.au=MacPherson,%20Ross%20D&rft.date=2002-02-01&rft.volume=38&rft.issue=2&rft.spage=135&rft.pages=135-&rft.issn=1699-3993&rft_id=info:doi/10.1358/dot.2002.38.2.668325&rft_dat=%3Cpubmed_cross%3E12532190%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/12532190&rfr_iscdi=true